A study in healthy volunteers and patients with liver cirrhosis to assess the effects of age, gender, and stable liver disease on the clearance of cholyl-lysyl-fluorescein (NRL972)
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
72
UMHAPT St Ivan Rilski's University Hospital
Sofia, Bulgaria
Clearance of NRL972 in healthy subjects and patients with hepatic cirrhosis
Time frame: Up to 4 hrs post administration of NRL972
Adverse events and changes in physical findings from baseline
Time frame: Up to 4 hours post-dosing
Effects on vital signs: blood pressure, pulse rate
Time frame: Up to 4 hours post-dosing
Effects on electrocardiogram
Time frame: Up to 4 hours post-dosing
Changes in haematology, clinical chemistry, urinalysis
Time frame: Up to 4 hours post-dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Single intravenous dose of 2 mg NRL972
Single intravenous dose of 2 mg NRL972
Single intravenous dose of 2 mg NRL972